2006/12/01 by Ignacio Conget Donlo, David Contreras, José Manuel Rodríguez Barrios +3 · 1 citation
Medicine · #Continuous glucose monitoring #Diabetes Management and Research #Diabetes Treatment and Management #Diabetes mellitus #Endocrinology #Health care #Hyperglycemia and glycemic control in critically ill and hospitalized patients #Medical costs #Medicine #Type 1 diabetes
paper · pdf · doi:10.1590/s1135-57272006000600008
openalex publication_date 2006/12/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/08/01
BACKGROUND: The use of continuous subcutaneous insulin infusion (CSII) for treating Type I diabetes mellitus (DM1) has been related to better metabolic control compared it to daily multiple insulin injections (DMI) and thus to a lowering of the related costs. However, this therapy is now being used to a lesser extent due, at least partially, to the higher initial cost of purchase. This study is aimed at estimating the clinical and economic consequences of using CSII as compared to DMI by means of a cost-utility analysis. METHODS: A mathematical simulation model was adapted using nationwide clinical and economic data to simulate the long-term clinical and economic consequences for a DM1 patient. The time horizon was the patient's lifetime, including only direct healthcare costs and updating both costs and benefits at an annual 3% rate. RESULTS: In the basecase, the patients treated using CSII gained 0.890 years (p < 0.05) and 0.852 QALYs (p < 0.05). CSII treatment gives rise to an incremental average cost of 25,523 Euro (p < 0.05) per patient treated, which gave us an incremental cost- utility ratio of 29,947 Euro-QALY [CI 95% (29,519; 30,375)]. CONCLUSIONS: The improvement in the glucose control among those patients treated using CSII was related to an overall lower cost in the handling of DM1 patients, which was found to have a favourable cost-utility ratio in comparison to conventional MDI treatment.